Oppenheimer Initiates Coverage On Marinus Pharmaceuticals with Outperform Rating, Announces $6 Price Target

Oppenheimer analyst Jay Olson initiates coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) with a Outperform rating and a $6 price target.

Benzinga · 12/20/2019 11:27

Oppenheimer analyst Jay Olson initiates coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) with a Outperform rating and a $6 price target.